TY - JOUR T1 - Novel surrogate virus neutralization test reveals low serum neutralizing anti-SARS-CoV-2-S antibodies levels in mildly affected COVID-19 convalescents JF - medRxiv DO - 10.1101/2020.07.12.20151407 SP - 2020.07.12.20151407 AU - Berislav Bošnjak AU - Saskia Catherina Stein AU - Stefanie Willenzon AU - Anne Katrin Cordes AU - Wolfram Puppe AU - Günter Bernhardt AU - Inga Ravens AU - Christiane Ritter AU - Christian R. Schultze-Florey AU - Nina Gödecke AU - Jörg Martens AU - Hannah Kleine-Weber AU - Markus Hoffmann AU - Anne Cossmann AU - Mustafa Yilmaz AU - Isabelle Pink AU - Marius M. Hoeper AU - Georg M.N. Behrens AU - Stefan Pöhlmann AU - Rainer Blasczyk AU - Thomas F. Schulz AU - Reinhold Förster Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/14/2020.07.12.20151407.abstract N2 - Neutralizing antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into cells using surface-expressed angiotensin-converting enzyme 2 (ACE2). We developed a surrogate neutralization test (sVNT) to assess at what degree serum antibodies interfere with the binding of SARS-CoV-2-S-RBD to ACE2. The sVNT revealed neutralizing anti-SARS-CoV-2-S antibodies in the sera of 90% of mildly and 100% of severely affected coronavirus-disease-2019 (COVID-19) convalescent patients. Importantly, sVNT results correlated strongly to the results from pseudotyped-vesicular stomatitis virus-vector-based neutralization assay and to levels of anti-SARS-CoV-2-S1 IgG and IgA antibodies. Moreover, levels of neutralizing antibodies also correlated to duration and severity of clinical symptoms, but not patient age or gender. These findings together with the sVNT will not only be important for evaluating the prevalence of neutralizing antibodies in a population but also for identifying promising plasma donors for successful passive antibody therapy.Competing Interest StatementThe authors have declared no competing interest.Funding Statement: This work was supported by Deutsche Forschungsgemeinschaft, DFG Excellence Strategy EXC 2155 RESIST Project ID39087428 and by funds of the state of Lower Saxony (1476103184 CORONA11/20) to RF and (1476103184 CORONA12/20) to TFS and by funds of BMBF (RAPID consortium, 01K11723D).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Studies investigating serum samples from healthy controls and COVID-19 patients were approved by the HMS institutional review board (#9001_BO_K2020 and #7901_BO_K2018).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request to the corresponding authors. ER -